5RICHARDSON PG,BARLOGIE B,BERENSON J,et al A phase Ⅱ study of bovtezomib in relapsed,refractory myeloma [J]. N EngI J Med,2003,348(26) : 2609-2617.
6BURGER AM,SETHAK. The Ubiquitin-media protein degradation pathway in cancer:theropeutic implications [J]. Eur J Cancer, 2004,40(9):2217.
7JAQANNATH S,TOMTHON W,JACKJONS. et al. Bortezomib therapy alone ang in combination with dexamethansone for previously untreated symptomatic multiple myeloma[ J ]. Br J Haematol, 2005 , 129 (6) :776-783.
8Fermand J P,Ravaud P,Chevret S,et al.High-dose therapy and autologous peripheral blood stem cell transplantation inmultiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial[].Blood.1998
9Adams J,Kauffman M.Development of the proteasome inhibitor Velcade (Bortezomib)[].Cancer Investigation.2004
10Hideshima,T.,Chauhan,D.,Richardson,P.,Anderson,K. C.Identification and validation of novel therapeutic targets for multiple myeloma[].Journal of Clinical Oncology.2005
